[go: up one dir, main page]

WO1998019702A1 - Acellular pertussis vaccine with diphthriae- and tetanus-toxoids - Google Patents

Acellular pertussis vaccine with diphthriae- and tetanus-toxoids Download PDF

Info

Publication number
WO1998019702A1
WO1998019702A1 PCT/EP1997/006180 EP9706180W WO9819702A1 WO 1998019702 A1 WO1998019702 A1 WO 1998019702A1 EP 9706180 W EP9706180 W EP 9706180W WO 9819702 A1 WO9819702 A1 WO 9819702A1
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
dose
per
composition according
fha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1997/006180
Other languages
French (fr)
Inventor
Patrick Florent
Jean Stephenne
Christian Vandecasserie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL12953097A priority Critical patent/IL129530A/en
Priority to SI9730394T priority patent/SI0941117T1/en
Priority to DK97950137T priority patent/DK0941117T3/en
Priority to BRPI9712917A priority patent/BRPI9712917B8/en
Priority to HU9904287A priority patent/HU224126B1/en
Priority to BR9712917-8A priority patent/BR9712917A/en
Priority to DK02075821T priority patent/DK1240905T5/en
Priority to JP52107098A priority patent/JP3980652B2/en
Priority to AT97950137T priority patent/ATE222773T1/en
Priority to HK00101495.8A priority patent/HK1022638B/en
Priority to EP97950137A priority patent/EP0941117B1/en
Priority to AU53196/98A priority patent/AU710475B2/en
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Priority to CA002271008A priority patent/CA2271008C/en
Priority to NZ335384A priority patent/NZ335384A/en
Priority to DE69715031T priority patent/DE69715031T2/en
Publication of WO1998019702A1 publication Critical patent/WO1998019702A1/en
Priority to NO19992156A priority patent/NO320186B1/en
Priority to PL97333127A priority patent/PL188460B1/en
Anticipated expiration legal-status Critical
Priority to US10/838,577 priority patent/US8623380B2/en
Priority to LU91183C priority patent/LU91183I2/en
Priority to NO2006005C priority patent/NO2006005I2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • 69K is an important component of acellular pertussis vaccines (Pa vaccines) for the effective prevention of pertussis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides a diphtheria, tetanus and pertussis vaccine comprising a low dose of each of diphtheria toxoid (D), tetanus toxoid (T), pertussis toxin (PT), filamentous haemagglutinin (FHA) and pertactin (69K). The vaccine maintains an ability to prevent pertussis while showing exceptionally low reactogenicity. Combination vaccines comprising additional antigens are also provided.

Description

ACELLULAR PERTUSSIS VACCINE WITH DIPHTHRIAE- AND TETANUS-TOXOIDS
The present invention relates to new vaccine formulations, comprising a low dose of the 69 da outer membrane protein of Bordetella pertussis (hereinafter termed '69K' or '69K antigen' or pertactin, disclosed in European Patent 0 162 639
Recombinant 69K (P69) has been described by N F Fairweather et al, Symposium On Pertussis (Bethesda), 26-28 September 1990) The invention in particular relates to a vaccine comprising more than one antigen, especially a multivalent vaccine, that is a vaccine for the amelioration or treatment of more than one disease state, in which a low dose of 69 is present The present invention also relates to the production and use of such vaccines in medicine
It is known that 69K is an important component of acellular pertussis vaccines (Pa vaccines) for the effective prevention of pertussis
A study on the dose responses of 5 acellular pertussis vaccines in healthy adults was published by the US National Institutes of Health (NTH) in May 1996 by Keitel, W. et al
69K-containing vaccines including 'trivalent' vaccines comprising antigens against diphtheria (D), tetanus (T) and pertussis (Pa) have been described in clinical trials conducted in Italy and Sweden and are marketed [for example under the Trade Mark INFANP X-DTPa (SmithKline Beecham Biologicals)] Typically the pertussis component of such vaccines comprises pertussis toxin (PT), filamentous haemagglutinin (FHA) and 69K In LNFANRIX-DTPa (Trade Mark) the amounts of D T PT FHA 69K are typically 25 Lf lOLf 25ug 25ug 8ug per 0 5 ml dose of bulk vaccine Other multivalent vaccines comprising 69K are also known, for example vaccines comprising an antigen against hepatitis B and antigens against diphtheria, tetanus and pertussis (Hep B, DTPa) were described in WO 93/24148 In such formulations the quantity of D T PT FHA 69K was given as 25 Lf lOLf 25ug 25ug 8ug per 0 5 ml dose of bulk vaccine It has now been found that a diphtheria, tetanus and pertussis vaccine containing a low dose of each of diphtheria toxoid (D), tetanus toxoid (T), PT, FHA and 69K (herein such a low dose formulation is abbreviated to a dtpa vaccine) maintains an ability to prevent pertussis (and is highly effective in this respect) while having the advantage of showing exceptionally low reactogenicity Within the limits described herein such vaccines are safe when administered to human subjects and induce rapid protection against infection. In combination vaccines comprising dtpa and other antigens it has been found that there is no interference, i.e. such vaccines show no loss of immunogenicity, and are effective when administered to humans.
In particular the vaccines of this invention are suitable for administration to children as a booster following prior administration of one or more (typically up to about 3) doses of a vaccine comprising a higher dose of D, T, and Pa antigens such as the LNFANRIX-DTPa vaccine described above (D:T:PT.FHA:69K = 25 Lf: 1 OLf 25ug:25ug:8ug per 0.5 ml dose of bulk vaccine). The vaccines of this invention are also of great value for administration to adults and adolescents
Accordingly the present invention provides a vaccine composition comprising a low dose of each of the antigens D, T, PT, FHA and 69K (i.e a dtpa vaccine composition). It will be understood that the vaccine composition of the invention is formulated with a suitable carrier or adjuvant.
By dtpa vaccine or dtpa vaccine composition is meant a dose wherein the concentration of D per 0.5 ml dose of bulk vaccine does not exceed 5 Lf and is preferably 1-4 Lf, more preferably about 2 Lf; the concentration of T per 0.5 ml dose of bulk vaccine does not exceed 10 Lf and is preferably 2.5 - 7.5 Lf, more preferably about 5Lf: the concentration of PT per 0.5 ml dose of bulk vaccine does not exceed 10 ug and is preferably 2-10 ug, more preferably about 8ug; the concentration of FHA per 0 5 ml dose of bulk vaccine does not exceed 10 ug and is preferably 2-10 ug, more preferably about 8ug; and the concentration of 69K does not exceed 4 micrograms per 0.5 ml dose of bulk vaccine and is preferably in the range 0 5ug to 3 ug per 0.5 ml dose of bulk vaccine More preferably the concentration of 69K in the vaccine is in the range 2 to 3ug, more preferably aproximately 2.5ug pertactin per 0 5 ml dose of bulk vaccine.
In one aspect the the vaccine compositions of the invention may, for example, comprise (approximately) PT (2 5ug), FHA (2.5ug), 69K (0 8ug) per 0 5 ml dose of bulk vaccine
_ ι . In a preferred aspect the vaccine compositions of the invention comprise (approximately) PT (8ug), FHA (8ug), 69K (2.5ug) per 0.5 ml dose of bulk vaccine.
In an especially preferred aspect the vaccine compositions of the invention comprise PT (8ug), FHA (8ug), 69K (2.5ug), D (2 Lf) and T (5 Lf) per 0.5 ml dose of bulk vaccine. This was used in the 'dtpa 005' study reported below.
In another preferred aspect the vaccine composition of the invention has the amount of the D component increased to 2.5Lf.
In a further preferred aspect the dtpa tricomponent vaccine composition is as follows: PT 8 μg FHA 8 μg 69K 2.5 μg diphtheria toxoid >= 2 IU tetanus toxoid >= 20 IU Al salts 0.3 mg phenoxyethanol 2.5 mg
This was used in the study in adolescents known as 'dtpa 003', results of which are given below.
Optionally the PT component may be recombinant (for example as described in European Patent Applications EP 0 306 318, EP 0 322 533, EP 0 396 964, EP 0 322 115 and EP 0 275 689) or the PT component may be toxoided, for example as described in EP 0 515 415. See also EP 0 427 462 and WO 91/12020 for the preparation of pertussis antigens.
In a further aspect the invention provides a vaccine composition comprising dtpa (as hereinabove defined) in combination with one or more additional antigens, particularly an antigen against hepatitis B (Hep B) (i.e. a Hep B - dtpa vaccine). Such multivalent vaccines are generally as described in WO 93/24148 except that a low dose of each of D, T, PT, FHA and 69K as hereinabove defined is used in the formulation. As described in WO 93/24148 the hepatitis B antigen is preferably hepatitis B surface antigen. The dose of hepatitis B surface antigen will normally be in the range 5-20ug per 0 5 ml dose of bulk vaccine
The preparation of Hepatitis B surface antigen (HBsAg) is well documented See for example, Harford et al in Develop Biol Standard 54, page 125 ( 1983), Gregg et al in Biotechnology. 5, page 479 ( 1987), EP-A- 0 226 846, EP-A-0 299 108 and references therein.
As used herein the expression 'Hepatitis B surface antigen' or 'HBsAg' includes any HBsAg antigen or fragment thereof displaying the antigenicity of HBV surface antigen. It will be understood that in addition to the 226 amino acid sequence of the HBsAg S antigen (see Tiollais et al, Nature, 3 17, 489 (1985) and references therein) HBsAg as herein described may, if desired, contain all or part of a pre-S sequence as described in the above references and in EP-A- 0 278 940 HBsAg as herein described can also refer to variants, for example the 'escape mutant' described in WO 91/14703 In a further aspect the HBsAg may comprise a protein described as L* in European Patent Application Number 0 414 374, that is to say a protein, the amino acid sequence of which consists of pans of the amino acid sequence of the hepatitis B virus large (L) protein (ad or ay subtype), characterised in that the amino acid sequence of the protein consists of either:
(a) residues 12 - 52, followed by residues 133 - 145, followed by residues 175 - 400 of the said L protein; or
(b) residue 12, followed by residues 14 - 52, followed by residues 133 - 145, followed by residues 175 - 400 of the said L protein.
HBsAg may also refer to polypeptides described in EP 0 198 474 or EP 0 304 578. Normally the HBsAg will be in particle form. It may comprise S protein alone or may be as composite particles, for example (L*,S) wherein L* is as defined above and S denotes the S-protein of hepatitis B surface antigen.
Preferably the HBsAg will be adsorbed on aluminium phosphate as described in WO93/24148 Other antigens may be adsorbed onto aluminium phosphate or aluminium hydroxide but in some cases satisfactory results will be obtained onlv if the other antigen is adsorbed on aluminium phosphate. Other antigens may included in vaccines of the invention to provide other multivalent vaccines for paediatric, adolescent or adult use. Suitable said other antigens may, for example, comprise those known in the art to provide protection against Haemophilus influenzae b (Hib) and/or polio (LPV) and/or hepatitis A, as described in WO 93/24148.
Suitable components for use in such vaccines are already commercially available and details may be obtained from the World Health Organisation. For example the LPV component may be the Salk inactivated polio vaccine. The component affording protection against Hepatitis A is preferably the product known as Ηavrix' (SmithKline Beecham Biologicals) which is a killed attenuated vaccine derived from the HM- 175 strain of HAV [see 'Inactivated Candidate Vaccines for Hepatitis A' by F.E. Andre, A Hepburn and E.D'Hondt, Prog Med Virol. Vol 37, pages 72-95 (1990) and the product monograph Ηavrix' published by SmithKline Beecham Biologicals (1991)]. Conveniently, the Hepatitis B component may comprise the 'S' antigen as already present in the commercial vaccine 'Engerix-B' (SmithKline Beecham Biologicals).
The amount of antigen in each vaccine dose is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical vaccinees. Such amount will vary depending on which specific immunogens are employed. Generally it is expected that each dose will comprise 15-50ug of total immunogen. Booster injections may be given. Booster injections of vaccines according to the invention in subjects primed with a vaccine comprising whole cell pertussis (Pw) are as efficacious as in subjects primed with a vaccine comprising acellular pertussis (Pa). In general the vaccine formulations of any aspect of the invention can be prepared as follows. The required components are adsorbed onto a suitable adjuvant, most especially aluminium hydroxide or aluminium phosphate. After allowing time for complete and stable adsorption of the respective components, the different components can be combined under appropriate conditions. In a preferred aspect of preparing a combined Hepatitis B-containing vaccine composition according to the invention there is provided a method which involves mixing aluminium phosphate-adsorbed HBsAg with one or more aluminium hydroxide or aluminium phosphate-adsorbed antigens.
The following examples illustrate the invention:
Example 1: Preparation of a dtpa vaccine formulation and study in adults
The dtpa vaccine according to the invention was prepared by standard methodology in accordance with the procedure for formulating a higher dose DTPa vaccine described in WO 93/24148.
Results obtained with the vaccine in a clinical study in adults coded 'dtpa 005' are shown in the appended figures, in which dtpa is used to signify a vaccine according to the invention and PRN is an abbreviation for pertactin (69K). The abbreviation dT is used to signify the standard diphtheria-tetanus vaccine obtainable from Behringwerke comprising a low dose of diphtheria toxoid and a higher dose of tetanus toxoid.
An open, randomised single dose study was carried out in adults aged 18-45 in Belgium using dtpa formulated as described above in 60 subjects as compared with dT (Behring) in 60 subjects. For the dtpa group 28 females were studied (mean age 33 years) and 32 males were studied (mean age 33 years). For the dT group 32 females were studed (mean age 34 years) and 28 males were studied (mean age 35 years).
Excluded were those who had had a diphtheria, tetanus or pertussis vaccination within the last 10 years or pertussis disease within the last 5 years. Sera were obtained pre and I month post vaccination with a solicited follow-up after 15 days and an unsolicited follow-up after 30 days.
Reactogenicity data, antibody responses, anti-PT results, anti-FHA results and anti-PRN (pertactin) results are shown in the appended figures.
In the appended figures, results are also shown for the monovalent pa vaccine used in the NTH (AAPT) studies reported by Keitel et al References to SmithKline Beecham's (SB's) High, Medium (SB-Med) and Low formulations contain, respectively, PT (25ug), FHA (25ug) and 69K (8ug) (High), PT (8ug), FHA (8ug) and 69K (2 5ug) (Medium), and PT (2 5ug), FHA (2 5ug) and 69K (0 8ug) (Low)
The abbreviation 'ug' stands for micrograms
It may be seen that a dtpa vaccine according to the invention was safe and immunogenic in adults Furthermore immune responses to candidate vaccines of the invention in adults appeared to be at least several times higher than observed for known higher dose DTPa vaccines previously administered to US, German and Italian infants
Example 2: Study in adolescents ('dtpa 003')
An open, randomised single dose study was carried out in adolescents aged 10- 12 in Finland using dtpa formulated as descπbed above in 120 subjects as compared with dT (Finland) in 120 subjects The same lot of dtpa vaccine of the invention was used in both the dtpa 005 and dtpa 003 studies.
The commercially available (Finland) dT contained, diphtheria toxoid >= 4 IU tetanus toxoid >= 40 IU
For the dtpa group 70 females were studied (mean age 10 9 years) and 49 males were studied (mean age 10 8 years) For the dT group 62 females were studed (mean age 10 9 years) and 56 males were studied (mean age 1 1 0 years)
The subjects included in the trial had received up to 4 doses of DTPw within the first 2 years of life.
Subjects excluded from the study were those who had had D, T or P vaccination after the second year of life or a history of diphtheria, tetanus or pertussis disease
Sera were obtained pre and 1 month post vaccination with a solicited follow-up after 15 days and an unsolicited follow-up after 30 days
Reactogenicity data, antibody responses, anti-PT results, anti-FHA results and anti-PRN (pertactin) results are shown in the appended figures It may be seen from the results that a dtpa vaccine according to the invention was safe and immunogenic in adolescents Note: In the figures, results relating to the antibody responses for the study in adults (dtpa 005) and the study in adolescents (dtpa 003) show the distribution of . individual pre- and post-vaccination anti-diphtheria and anti-tetanus antibody titres of subjects included in the overall analysis of immunogenicity (>=0.1 IU/ml being the cut- off determined for protection). Also given are the geometric mean anti-diphtheria and anti-tetanus antibody titres in IU/ml.
The figures for the dtpa 005 and dtpa 003 studies which illustrate anti-PT, anti- FHA and anti-PRN titers show the vaccine response rate (in % of the total number of subjects - n -) and geometric mean antibody titres (GMT, in EU/ml) for the vaccine components PT, FHA and PRN of subjects included in the overall analysis of immunogenicity.
Example 3: Preparation of a Hep B - dtpa vaccine
The formulation was prepared exactly as in Example 5 of WO93/24148 except that low doses of D, T, PT, FHA and 69K as hereinabove defined were used to make up 0.5 ml dose of bulk vaccine.
In a preferred composition the amounts of dtpa were approximately as follows: PT (8ug), FHA (8ug), 69K (2.5ug), D (2 Lf) and T (5 Lf) per 0.5 ml dose of bulk vaccine.
In another preferred composition the amount of D was increased to 2.5Lf The amount of hepatitis B surface antigen in the vaccine composition can vary from 5-20 ug and is typically lOug per 0.5 ml dose of bulk vaccine.

Claims

Claims
1. A vaccine composition comprising diphtheria (D), tetanus (T) and acellular pertussis (Pa) antigens and an adjuvant, wherein wherein the concentration of D per 0.5 ml dose of bulk vaccine does not exceed 5 Lf and is preferably 1-4 Lf, more preferably about 2 Lf; the concentration of T per 0.5 ml dose of bulk vaccine does not exceed 10 Lf and is preferably 2.5 - 7.5 Lf, more preferably about 5Lf and the Pa component comprises PT (pertussis toxoid), FHA (filamentous hemagglutinin) and pertactin (69K) wherein the concentration of PT per 0.5 ml dose of bulk vaccine does not exceed 10 ug and is preferably 2-10 ug, more preferably about 8ug; the concentration of FHA per 0.5 ml dose of bulk vaccine does not exceed 10 ug and is preferably 2-10 ug, more preferably about 8ug; and the concentration of 69K does not exceed 4 micrograms per 0.5 ml dose of bulk vaccine and is preferably in the range 0.5ug to 3 ug, more preferably 2 to 3ug, more preferably aproximately 2.5ug per 0.5 ml dose of bulk vaccine.
2. A vaccine composition according to claim 1 having the composition: PT (8ug), FHA (8ug), 69K (2.5ug), D (2 Lf) and T (5 Lf) per 0.5 ml dose of bulk vaccine.
3. A vaccine composition according to any one of claims 1 or 2 which additionally comprises one or more additional antigens.
4. A vaccine composition according to claim 3 wherein an additional antigen is hepatitis B surface antigen.
5. A vaccine composition according to claim 4 wherein the hepatitis B surface antigen is the S-antigen of HBsAg.
6. A vaccine composition according to claim 3 or claim 4 wherein an additional antigen is present which provides immunity against one or more of Hib, polio or hepatitis A infection.
7. A vaccine composition according to any previous claim wherein the adjuvant used in the formulation comprises aluminium hydroxide.
8. A vaccine composition according to any previous claim wherein the adjuvant used in the formulation comprises aluminium phosphate.
9. A method of preventing disease in children or adolescent or adult subjects, which comprises vaccinating the subjects with a vaccine composition according to any one of claims 1 to 8.
PCT/EP1997/006180 1996-11-07 1997-11-04 Acellular pertussis vaccine with diphthriae- and tetanus-toxoids Ceased WO1998019702A1 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
EP97950137A EP0941117B1 (en) 1996-11-07 1997-11-04 Acellular pertussis vaccine with diphthriae- and tetanus-toxoids
DK97950137T DK0941117T3 (en) 1996-11-07 1997-11-04 Acellular pertussis vaccine with diphtheria and tetanus toxoids
BRPI9712917A BRPI9712917B8 (en) 1996-11-07 1997-11-04 vaccine composition comprising diphtheria, tetanus and pertussis toxoids.
HU9904287A HU224126B1 (en) 1996-11-07 1997-11-04 Acellular pertussis vaccine with diphtheria and tetanus toxoids
BR9712917-8A BR9712917A (en) 1996-11-07 1997-11-04 Acellular pertussis vaccine with diphtheria and tetanus toxoids
SI9730394T SI0941117T1 (en) 1996-11-07 1997-11-04 Acellular pertussis vaccine with diphthriae- and tetanus-toxoids
JP52107098A JP3980652B2 (en) 1996-11-07 1997-11-04 Acellular pertussis vaccine with diphtheria and tetanus toxin
AT97950137T ATE222773T1 (en) 1996-11-07 1997-11-04 ACELLULAR PERTUSSIS VACCINE CONTAINING A DIPHTHERIA TOXOID AND A TETANUS TOXOID
HK00101495.8A HK1022638B (en) 1996-11-07 1997-11-04 Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
AU53196/98A AU710475B2 (en) 1996-11-07 1997-11-04 Acellular pertussis vaccine with diphtheria- and tetanus-toxoids
DK02075821T DK1240905T5 (en) 1996-11-07 1997-11-04 Acellular pertussis vaccine with diphtheria and tetanus toxoids
IL12953097A IL129530A (en) 1996-11-07 1997-11-04 Acellular pertussis vaccine with diphtheria and tetanus-toxoids
CA002271008A CA2271008C (en) 1996-11-07 1997-11-04 Acellular pertussis vaccine with diphtheria- and tetanus-toxoids
NZ335384A NZ335384A (en) 1996-11-07 1997-11-04 Acellular pertussis vaccine with diphthriae and tetanus toxoids
DE69715031T DE69715031T2 (en) 1996-11-07 1997-11-04 ACELLULAR PERTUSSIS VACCINE CONTAINING A DIPHTHERIA TOXOID AND A TETANUS TOXOID
NO19992156A NO320186B1 (en) 1996-11-07 1999-05-04 Vaccine composition comprising diphtheria, tetanus and acellular pertussis antigens, and use thereof for the manufacture of a medicament for the treatment and prevention of Bordetella pertussis infections.
PL97333127A PL188460B1 (en) 1996-11-07 1999-05-05 The vaccine composition and its use in the manufacture of a medicament
US10/838,577 US8623380B2 (en) 1996-11-07 2004-05-04 Acellular pertussis vaccine with diphthriae- and tetanus-toxoids
LU91183C LU91183I2 (en) 1996-11-07 2005-07-20 Combination of diphtheria toxoid, tetanus toxoid, pertussis toxoid, filamentous hemagglutinin, pertactin, and inactivated polio virus type 1, type 2 and type 3.
NO2006005C NO2006005I2 (en) 1996-11-07 2006-04-25 Diphtheria, tetanus, acellular whooping cough and polio antigens

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9623233.5 1996-11-07
GBGB9623233.5A GB9623233D0 (en) 1996-11-07 1996-11-07 Vaccine composition

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09284887 A-371-Of-International 1999-05-27
US09/827,785 Continuation US20010014331A1 (en) 1996-11-07 2001-04-06 Acellular pertussis vaccine with diphthriae-and tetanus-toxoids

Publications (1)

Publication Number Publication Date
WO1998019702A1 true WO1998019702A1 (en) 1998-05-14

Family

ID=10802615

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/006180 Ceased WO1998019702A1 (en) 1996-11-07 1997-11-04 Acellular pertussis vaccine with diphthriae- and tetanus-toxoids

Country Status (30)

Country Link
EP (2) EP1240905B3 (en)
JP (1) JP3980652B2 (en)
KR (1) KR100518044B1 (en)
CN (1) CN1130226C (en)
AR (1) AR011509A1 (en)
AT (2) ATE222773T1 (en)
AU (1) AU710475B2 (en)
BR (2) BR9712917A (en)
CA (1) CA2271008C (en)
CO (1) CO4910171A1 (en)
CY (2) CY2407B1 (en)
CZ (1) CZ295954B6 (en)
DE (3) DE69733285T3 (en)
DK (2) DK1240905T5 (en)
ES (2) ES2240647T7 (en)
GB (1) GB9623233D0 (en)
HK (1) HK1050473B (en)
HU (1) HU224126B1 (en)
IL (1) IL129530A (en)
LU (1) LU91183I2 (en)
NO (2) NO320186B1 (en)
NZ (1) NZ335384A (en)
PL (1) PL188460B1 (en)
PT (2) PT941117E (en)
SA (1) SA98181128B1 (en)
SI (2) SI1240905T1 (en)
TR (1) TR199900979T2 (en)
TW (1) TW471971B (en)
WO (1) WO1998019702A1 (en)
ZA (1) ZA979984B (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030678A1 (en) * 1998-11-26 2000-06-02 Aventis Pasteur Msd Multivalent t.d. polio vaccine against at least diphtheria, poliomyelitis and tetanus
WO2002055105A1 (en) * 2001-01-10 2002-07-18 Lg Life Sciences Ltd. Manufacturing method of combined vaccine
KR100374813B1 (en) * 2000-04-07 2003-03-03 녹십자백신 주식회사 The preparation method of quadrivalent combination vaccine including diphtheria toxoid, tetanus toxoid, acellular pertussis antigens and hepatitis b surface antigen
WO2008020328A3 (en) * 2006-08-16 2008-06-19 Novartis Ag Manufacture of booster vaccines having reduced antigen doses
WO2010067201A3 (en) * 2008-12-11 2010-09-16 Novartis Ag MIXING LYOPHILISED MENINGOCOCCAL VACCINES WITH D-T-Pa VACCINES
CN102363041A (en) * 2011-11-17 2012-02-29 成都欧林生物科技股份有限公司 Method for preparing preservative-free vaccine
WO2014024026A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against rsv and b. pertussis
WO2013132041A3 (en) * 2012-03-08 2014-04-10 Novartis Ag Adjuvanted formulations of booster vaccines
US8916173B2 (en) 2013-03-08 2014-12-23 Crucell Holland B.V. Acellular pertussis vaccine
US9315530B2 (en) 2010-09-01 2016-04-19 Novartis Ag Adsorption of immunopotentiators to insoluble metal salts
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
EP3488865A1 (en) 2012-08-06 2019-05-29 GlaxoSmithKline Biologicals S.A. Method for eliciting in infants an immune response against rsv and b. pertussis
EP3492097A1 (en) 2013-08-05 2019-06-05 GlaxoSmithKline Biologicals S.A. Combination immunogenic compositions
US10603369B2 (en) 2011-03-02 2020-03-31 Glaxosmithkline Biologicals Sa Combination vaccines with lower doses of antigen and/or adjuvant

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
JP5007425B2 (en) * 2006-01-30 2012-08-22 財団法人ヒューマンサイエンス振興財団 Safety evaluation method for pertussis vaccine
CN102793915B (en) * 2012-07-25 2013-10-23 天津康希诺生物技术有限公司 Production method of acellular pertussis vaccine
CN103100081A (en) * 2012-12-26 2013-05-15 天津康希诺生物技术有限公司 Multi-valence combined vaccine
CN114748616A (en) * 2022-05-23 2022-07-15 中国医学科学院医学生物学研究所 Acellular diphtheria-pertussis-tetanus combined vaccine for adults and teenagers and preparation method thereof
CN117417419B (en) * 2023-01-10 2024-04-19 康希诺生物股份公司 Pertussis toxin detoxification method and cell-free pertussis combined vaccine
CN119524117B (en) * 2025-01-23 2025-09-23 康希诺生物股份公司 Immunogenic composition, diphtheria, tetanus and pertussis combined vaccine and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024148A1 (en) * 1992-05-23 1993-12-09 Smithkline Beecham Biologicals (S.A.) Combined vaccines comprising hepatitis b surface antigen and other antigens

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI861417A0 (en) 1985-04-15 1986-04-01 Endotronics Inc HEPATITIS B YTANTIGEN FRAMSTAELLD MED REKOMBINANT-DNA-TEKNIK, VACCIN, DIAGNOSTISKT MEDEL OCH CELLINJER SAMT FOERFARANDEN FOER FRAMSTAELLNING DAERAV.
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
AP56A (en) 1987-01-30 1989-09-26 Smithkline Biologicals S A Hepatitis B virus surface antigens and hybrid antigehs containing them.
EP1088830A3 (en) 1987-06-22 2004-04-07 Medeva Holdings B.V. Hepatitis b surface antigen particles
ATE105858T1 (en) 1987-07-17 1994-06-15 Rhein Biotech Ges Fuer Biotech DNA MOLECULES ENCODING FMDH CONTROL PART AND STRUCTURAL GENES FOR A PROTEIN WITH FMDH ACTIVITY AND THEIR APPLICATIONS.
ATE159031T1 (en) 1989-07-25 1997-10-15 Smithkline Biolog ANTIGENS AND METHODS FOR THE PRODUCTION THEREOF
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024148A1 (en) * 1992-05-23 1993-12-09 Smithkline Beecham Biologicals (S.A.) Combined vaccines comprising hepatitis b surface antigen and other antigens

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EDWARDS K M ET AL: "Comparison of 13 acellular pertussis vaccines: Overview and serologic response.", PEDIATRICS 96 (3 PART 2). 1995. 548-557. ISSN: 0031-4005, XP002058253 *
GRECO D ET AL: "A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group", NEW ENGLAND JOURNAL OF MEDICINE, vol. 334, no. 6, 8 February 1996 (1996-02-08), pages 341 - 348, XP002058255 *
PODDA A ET AL: "Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine.", JOURNAL OF PEDIATRICS 124 (6). 1994. 921-926. ISSN: 0022-3476, XP002058254 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030678A1 (en) * 1998-11-26 2000-06-02 Aventis Pasteur Msd Multivalent t.d. polio vaccine against at least diphtheria, poliomyelitis and tetanus
KR100374813B1 (en) * 2000-04-07 2003-03-03 녹십자백신 주식회사 The preparation method of quadrivalent combination vaccine including diphtheria toxoid, tetanus toxoid, acellular pertussis antigens and hepatitis b surface antigen
WO2002055105A1 (en) * 2001-01-10 2002-07-18 Lg Life Sciences Ltd. Manufacturing method of combined vaccine
CN101522217B (en) * 2006-08-16 2014-07-16 葛兰素史密丝克莱恩生物有限公司 Manufacture of booster vaccines having reduced antigen doses
WO2008020328A3 (en) * 2006-08-16 2008-06-19 Novartis Ag Manufacture of booster vaccines having reduced antigen doses
WO2010067201A3 (en) * 2008-12-11 2010-09-16 Novartis Ag MIXING LYOPHILISED MENINGOCOCCAL VACCINES WITH D-T-Pa VACCINES
US20110311575A1 (en) * 2008-12-11 2011-12-22 Novartis Ag MIXING LYOPHILISED MENINGOCOCCAL VACCINES WITH D-T-Pa VACCINES
US9511132B2 (en) 2008-12-11 2016-12-06 Glaxosmithkline Biologicals Sa Mixing lyophilised meningococcal vaccines with D-T-Pa vaccines
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
US9315530B2 (en) 2010-09-01 2016-04-19 Novartis Ag Adsorption of immunopotentiators to insoluble metal salts
US10098949B2 (en) 2010-09-01 2018-10-16 Glaxosmithkline Biologicals S.A. Adsorption of immunopotentiators to insoluble metal salts
US10603369B2 (en) 2011-03-02 2020-03-31 Glaxosmithkline Biologicals Sa Combination vaccines with lower doses of antigen and/or adjuvant
CN102363041A (en) * 2011-11-17 2012-02-29 成都欧林生物科技股份有限公司 Method for preparing preservative-free vaccine
WO2013132041A3 (en) * 2012-03-08 2014-04-10 Novartis Ag Adjuvanted formulations of booster vaccines
US9375471B2 (en) 2012-03-08 2016-06-28 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
US9931399B2 (en) 2012-03-08 2018-04-03 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
US10842868B2 (en) 2012-03-08 2020-11-24 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
WO2014024026A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against rsv and b. pertussis
EP3488865A1 (en) 2012-08-06 2019-05-29 GlaxoSmithKline Biologicals S.A. Method for eliciting in infants an immune response against rsv and b. pertussis
US8916173B2 (en) 2013-03-08 2014-12-23 Crucell Holland B.V. Acellular pertussis vaccine
EP3492097A1 (en) 2013-08-05 2019-06-05 GlaxoSmithKline Biologicals S.A. Combination immunogenic compositions

Also Published As

Publication number Publication date
NO2006005I1 (en) 2006-05-08
EP0941117A1 (en) 1999-09-15
IL129530A (en) 2005-11-20
DE69715031D1 (en) 2002-10-02
ES2240647T7 (en) 2010-03-31
CA2271008C (en) 2008-07-22
ZA979984B (en) 1998-07-23
PT1240905E (en) 2005-09-30
SA98181128B1 (en) 2006-03-25
NZ335384A (en) 2000-10-27
CN1130226C (en) 2003-12-10
AR011509A1 (en) 2000-08-30
NO992156L (en) 1999-05-04
TW471971B (en) 2002-01-11
PT941117E (en) 2002-12-31
TR199900979T2 (en) 1999-07-21
DE69733285T2 (en) 2006-01-12
PL333127A1 (en) 1999-11-22
NO2006005I2 (en) 2010-04-12
BRPI9712917B1 (en) 2019-12-03
JP2001503422A (en) 2001-03-13
DE69715031T2 (en) 2003-05-08
HK1050473B (en) 2006-03-03
ATE295178T1 (en) 2005-05-15
BR9712917A (en) 1999-12-07
KR100518044B1 (en) 2005-09-30
CY2407B1 (en) 2004-09-10
DE69733285T3 (en) 2010-03-25
KR20000053092A (en) 2000-08-25
AU710475B2 (en) 1999-09-23
HUP9904287A3 (en) 2001-05-28
DK1240905T5 (en) 2010-01-11
SI0941117T1 (en) 2002-12-31
ATE222773T1 (en) 2002-09-15
EP1240905B1 (en) 2005-05-11
CZ295954B6 (en) 2005-12-14
PL188460B1 (en) 2005-02-28
GB9623233D0 (en) 1997-01-08
LU91183I2 (en) 2005-09-20
HUP9904287A1 (en) 2000-04-28
DE122005000046I1 (en) 2005-12-29
HU224126B1 (en) 2005-05-30
CY2568B1 (en) 2008-07-02
HK1022638A1 (en) 2000-08-18
CO4910171A1 (en) 2000-04-24
NO320186B1 (en) 2005-11-07
EP1240905A1 (en) 2002-09-18
DK1240905T3 (en) 2005-07-18
HK1050473A1 (en) 2003-06-27
BRPI9712917B8 (en) 2021-05-25
DK0941117T3 (en) 2002-11-18
JP3980652B2 (en) 2007-09-26
EP1240905B3 (en) 2009-08-26
AU5319698A (en) 1998-05-29
DE69733285D1 (en) 2005-06-16
CZ164099A3 (en) 1999-10-13
EP0941117B1 (en) 2002-08-28
SI1240905T1 (en) 2005-10-31
NO992156D0 (en) 1999-05-04
ES2182131T3 (en) 2003-03-01
CN1236321A (en) 1999-11-24
CA2271008A1 (en) 1998-05-14
IL129530A0 (en) 2000-02-29
ES2240647T3 (en) 2005-10-16

Similar Documents

Publication Publication Date Title
AU710475B2 (en) Acellular pertussis vaccine with diphtheria- and tetanus-toxoids
EP0835663B1 (en) Combined vaccines comprising Hepatitis B surface antigen and other antigens
US8623380B2 (en) Acellular pertussis vaccine with diphthriae- and tetanus-toxoids
HK1022638B (en) Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
MXPA99004278A (en) Acellular pertussisvaccine with diphthriae- and tetanus-toxoids
AU2012202099A1 (en) Combined vaccines comprising hepatitis B surface antigen and other antigens
PL174077B1 (en) Vaccine for preventing or treating hepatitis b infections and heterologous diseases, containing hepatitis b surface antigen (hbsag)
HK1021142B (en) Combined vaccines comprising hepatitis b surface antigen and other antigens
HK1011290B (en) Combined vaccines comprising hepatitis b surface antigen and other antigens
HK1147950A (en) Combined vaccines comprising hepatitis b surface antigen and other antigens
HK1137937A (en) Combined vaccines comprising hepatitis b surface antigen and other antigens

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97199491.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997950137

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 53196/98

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 1998 521070

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 335384

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2271008

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1999/00979

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1019997004016

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PV1999-1640

Country of ref document: CZ

Ref document number: PA/a/1999/004278

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 09284887

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997950137

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1999-1640

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 53196/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1019997004016

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1997950137

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1019997004016

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: PV1999-1640

Country of ref document: CZ